Piroxicam - Nanoform
Alternative Names: NanoformedTM piroxicam; Piroxicam immediate release - Nanoform; Piroxicam nanoparticlesLatest Information Update: 28 Jan 2025
At a glance
- Originator Nanoform
- Class Amides; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyridines; Small molecules; Thiazines
- Mechanism of Action Cyclo-oxygenase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Unspecified in Finland (PO, Capsule)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in United Kingdom (PO, Tablet)
- 18 May 2021 Final pharmacokinetics and adverse events data from a phase I trial in Unspecified indication released by Nanoform